These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
105 related items for PubMed ID: 30092863
1. Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. Zuur MA, van Asselt ADI, van 't Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC. Int J Tuberc Lung Dis; 2018 Sep 01; 22(9):991-999. PubMed ID: 30092863 [Abstract] [Full Text] [Related]
4. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany. Diel R, Hittel N, Schaberg T. Respir Med; 2015 May 01; 109(5):632-41. PubMed ID: 25862597 [Abstract] [Full Text] [Related]
5. Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. Law S, Benedetti A, Oxlade O, Schwartzman K, Menzies D. Eur Respir J; 2014 Feb 01; 43(2):566-81. PubMed ID: 23766335 [Abstract] [Full Text] [Related]
6. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H. Kekkaku; 2003 Oct 01; 78(10):611-7. PubMed ID: 14621568 [Abstract] [Full Text] [Related]
9. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E. Int J Tuberc Lung Dis; 2018 Aug 01; 22(8):918-925. PubMed ID: 29991402 [Abstract] [Full Text] [Related]
11. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. Ryckman TS, Schumacher SG, Lienhardt C, Sweeney S, Dowdy DW, Mirzayev F, Kendall EA. Lancet Glob Health; 2024 Jun 01; 12(6):e995-e1004. PubMed ID: 38762299 [Abstract] [Full Text] [Related]
12. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. Laurence YV, Griffiths UK, Vassall A. Pharmacoeconomics; 2015 Sep 01; 33(9):939-55. PubMed ID: 25939501 [Abstract] [Full Text] [Related]
15. Trends in drug-resistant tuberculosis after the implementation of the DOTS strategy in Shenzhen, China, 2000-2013. Zhu L, Yang YZ, Guan HY, Cheng SM, Jin YY, Tan WG, Wu QF, Liu XL, Zhao MG, Lu ZH, Jia ZW. Int J Tuberc Lung Dis; 2017 Jul 01; 21(7):759-765. PubMed ID: 28633700 [Abstract] [Full Text] [Related]
18. Performance comparison of four methods for detecting multidrug-resistant Mycobacterium tuberculosis strains. Al-Mutairi NM, Ahmad S, Mokaddas E. Int J Tuberc Lung Dis; 2011 Jan 01; 15(1):110-5. PubMed ID: 21276306 [Abstract] [Full Text] [Related]
19. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates. Sun Z, Zhang J, Song H, Zhang X, Li Y, Tian M, Liu Y, Zhao Y, Li C. Int J Tuberc Lung Dis; 2010 Nov 01; 14(11):1436-41, i. PubMed ID: 20937184 [Abstract] [Full Text] [Related]